| scholarly article | Q13442814 |
| P50 | author | Samuel Waxman | Q7412900 |
| Josep M. Llovet | Q37393125 | ||
| Yujin Hoshida | Q86559026 | ||
| Myron Schwartz | Q92668814 | ||
| Swan N Thung | Q114734967 | ||
| Victoria Tovar | Q114779878 | ||
| Clara Alsinet | Q114779880 | ||
| Philippa Newell | Q114779881 | ||
| Sasan Roayaie | Q114779882 | ||
| Judit Peix | Q114779885 | ||
| Jordi Bruix | Q37393143 | ||
| Beatriz Mínguez | Q38328449 | ||
| Matthew Meyerson | Q47451221 | ||
| Jordi Barretina Ginesta | Q55297543 | ||
| Vincenzo Mazzaferro | Q56380032 | ||
| Augusto Villanueva | Q56754203 | ||
| Derek Y Chiang | Q58328669 | ||
| Manel Solé | Q82840050 | ||
| P2093 | author name string | Alex H Ramos | |
| Scott L Friedman | |||
| Azra H Ligon | |||
| William R Sellers | |||
| Vesna Najfeld | |||
| Diana J Donovan | |||
| Amanda C LeBlanc | |||
| P2860 | cites work | AceView: a comprehensive cDNA-supported gene and transcripts annotation | Q21184141 |
| Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 | ||
| Characterizing the cancer genome in lung adenocarcinoma | Q24649926 | ||
| Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements | Q24804363 | ||
| Summaries of Affymetrix GeneChip probe level data | Q27860888 | ||
| PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas | Q28212534 | ||
| GenePattern 2.0 | Q29614171 | ||
| Diagnosis of multiple cancer types by shrunken centroids of gene expression | Q29615528 | ||
| Hepatocellular carcinoma pathogenesis: from genes to environment | Q29615767 | ||
| Hepatocellular carcinoma | Q29615841 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma | Q30014823 | ||
| A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. | Q31065517 | ||
| Inhibitory effect of antisense vascular endothelial growth factor RNA on the profile of hepatocellular carcinoma cell line in vitro and in vivo | Q33868191 | ||
| Gene expression patterns in human liver cancers | Q33898932 | ||
| A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. | Q34579605 | ||
| Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. | Q34710149 | ||
| Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays | Q35173717 | ||
| Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy | Q35785037 | ||
| Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma | Q35945177 | ||
| Common markers of proliferation. | Q36402204 | ||
| Molecular targeted therapies in hepatocellular carcinoma | Q37003665 | ||
| Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets | Q38400913 | ||
| EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma | Q40006245 | ||
| Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. | Q40174272 | ||
| Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations | Q40346356 | ||
| Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin | Q40435350 | ||
| Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis | Q41886998 | ||
| Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma | Q41918713 | ||
| Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis | Q43411713 | ||
| New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism | Q44226601 | ||
| Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. | Q44307079 | ||
| Disruption of beta-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice | Q44887152 | ||
| Application of comparative functional genomics to identify best-fit mouse models to study human cancer | Q45163567 | ||
| Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma | Q45416031 | ||
| Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. | Q46099165 | ||
| A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells | Q50115050 | ||
| Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. | Q50570121 | ||
| Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. | Q51939495 | ||
| Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. | Q52087746 | ||
| Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. | Q53343023 | ||
| Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor | Q71048188 | ||
| Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma | Q72522961 | ||
| Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma | Q74127310 | ||
| Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats | Q74127872 | ||
| Molecular pathogenesis of human hepatocellular carcinoma | Q74543031 | ||
| Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression | Q80516687 | ||
| Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma | Q80581929 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 6779-6788 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Focal gains of VEGFA and molecular classification of hepatocellular carcinoma | |
| P478 | volume | 68 |
| Q36804715 | A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma |
| Q42064611 | A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma |
| Q35991696 | A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions |
| Q37266967 | A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. |
| Q37149293 | A new, effective and high-yield approach for identifying liver tumor suppressors. |
| Q40512450 | A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets |
| Q34847309 | A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse |
| Q45869998 | A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. |
| Q82637929 | Abnormal nitrosothiol metabolism in hepatocellular carcinoma |
| Q37468851 | Accomplishments in 2008 in the management of hepatobiliary cancers. |
| Q38848537 | Advanced Hepatocellular Cancer: the Current State of Future Research |
| Q38521011 | Advances in targeted therapies for hepatocellular carcinoma in the genomic era. |
| Q92493872 | Amplification of the EGFR and CCND1 Are Coordinated and Play Important Roles in the Progression of Oral Squamous Cell Carcinomas |
| Q41997305 | Analysis of Genomes and Transcriptomes of Hepatocellular Carcinomas Identifies Mutations and Gene Expression Changes in the Transforming Growth Factor beta Pathway Short title: Prognostic significance of TGF-β signature in liver cancer. |
| Q42731069 | Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma |
| Q33770092 | Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer |
| Q55056739 | Association of genes on chromosome 6, GRIK2 , TMEM217 and TMEM63B (linked to MRPL14 ) with diabetic retinopathy. |
| Q24647547 | Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression |
| Q91791103 | Betulinic acid induces autophagy-mediated apoptosis through suppression of the PI3K/AKT/mTOR signaling pathway and inhibits hepatocellular carcinoma |
| Q89653705 | Biomarkers for hepatobiliary cancers |
| Q36012026 | Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma |
| Q92655534 | CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications |
| Q34002120 | Cancer gene discovery in hepatocellular carcinoma |
| Q35131908 | Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. |
| Q37890208 | Changing pathology with changing drugs: tumors of the gastrointestinal tract |
| Q35740345 | Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma |
| Q58689162 | Chronic Hypoxia Emerging as One of the Driving Forces behind Gene Expression and Prognosis of Hepatocellular Carcinoma |
| Q89952891 | Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations |
| Q87629733 | Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort |
| Q36359814 | Clinicopathological indices to predict hepatocellular carcinoma molecular classification |
| Q45906882 | Co-expression networks identify distinct immune infiltrates in hepatocellular carcinoma. |
| Q35968727 | Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib |
| Q33820376 | Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma |
| Q37899575 | Contribution of biomarkers and imaging in the management of hepatocellular carcinoma |
| Q38381518 | Copy number variation in archival melanoma biopsies versus benign melanocytic lesions. |
| Q34828696 | Correlation analysis connects cancer subtypes |
| Q34623730 | Current and future challenges in the surgical treatment of hepatocellular carcinoma: a review |
| Q64959827 | Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. |
| Q87604943 | Current management of hepatocellular carcinoma |
| Q35688107 | DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells |
| Q35103519 | DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. |
| Q58011404 | Das hepatozelluläre Karzinom |
| Q91584626 | Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma |
| Q35781589 | Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine. |
| Q47855807 | Deep Learning based multi-omics integration robustly predicts survival in liver cancer. |
| Q34791385 | Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice |
| Q37578218 | Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies |
| Q58602183 | Dimensions of hepatocellular carcinoma phenotypic diversity |
| Q92085113 | Discovering master regulators in hepatocellular carcinoma: one novel MR, SEC14L2 inhibits cancer cells |
| Q35625440 | Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6 |
| Q37966605 | Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers |
| Q40389227 | Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. |
| Q38155507 | Emerging signaling pathways in hepatocellular carcinoma. |
| Q59125682 | Evaluation and prediction of hepatocellular carcinoma prognosis based on molecular classification |
| Q36104399 | Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets |
| Q38182833 | Exploration of liver cancer genomes |
| Q36393332 | Exploring genomic profiles of hepatocellular carcinoma. |
| Q41563253 | Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. |
| Q102379407 | FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma |
| Q39282670 | Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment. |
| Q33807832 | Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma. |
| Q35557782 | GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers |
| Q33692511 | Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness |
| Q37002076 | Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma |
| Q41926688 | Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B. |
| Q36759564 | Gene-expression signature of vascular invasion in hepatocellular carcinoma. |
| Q28073241 | Genetic alterations in hepatocellular carcinoma: An update |
| Q33711037 | Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma |
| Q35084738 | Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. |
| Q26751655 | Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy |
| Q64108485 | Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma |
| Q37310665 | Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis |
| Q64089290 | Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib |
| Q37481324 | Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. |
| Q49884832 | Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. |
| Q58612842 | Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy |
| Q40519988 | Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups |
| Q39179262 | Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma |
| Q38970692 | Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts |
| Q57756376 | Hepatocellular carcinoma |
| Q38207012 | Hepatocellular carcinoma review: current treatment, and evidence-based medicine |
| Q39307416 | Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists |
| Q92104133 | Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets |
| Q36914691 | Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy |
| Q33895113 | Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies |
| Q90423324 | Heterogeneous beta-catenin activation is sufficient to cause hepatocellular carcinoma in zebrafish |
| Q59131888 | High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype |
| Q50199746 | Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer |
| Q38981016 | Human Hepatocellular Carcinomas with a Periportal Phenotype Have the Lowest Potential for Early Recurrence after Curative Resection |
| Q34102411 | IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. |
| Q37747546 | IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. |
| Q40478066 | IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype. |
| Q92015677 | Identification and characterization of sexual dimorphism‑linked gene expression profile in hepatocellular carcinoma |
| Q27310913 | Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish |
| Q34701235 | Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening |
| Q90705899 | Identification of cancer/testis antigen 2 gene as a potential hepatocellular carcinoma therapeutic target by hub gene screening with topological analysis |
| Q37315447 | Identification of driver genes in hepatocellular carcinoma by exome sequencing |
| Q37360110 | Identification of potential driver genes in human liver carcinoma by genomewide screening |
| Q53839990 | Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. |
| Q57494809 | Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence |
| Q102379530 | Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells |
| Q37096712 | Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases |
| Q34187221 | Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. |
| Q41434771 | Impact of epidermal growth factor receptor protein and gene alteration on Taiwanese hepatocellular carcinomas |
| Q38828541 | Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma |
| Q34432569 | Inflammatory cytokines promote the retrodifferentiation of tumor-derived hepatocyte-like cells to progenitor cells |
| Q45366925 | Integrated analysis of prognostic gene expression profiles from hepatitis B virus-positive hepatocellular carcinoma and adjacent liver tissue |
| Q39012316 | Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer |
| Q90576191 | Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications |
| Q28396741 | Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old |
| Q35658932 | Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas |
| Q53089247 | Integrative functional genomic delineation of the cascades of transcriptional changes involved in hepatocellular carcinoma progression. |
| Q28383106 | Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival |
| Q42143967 | Integrative genomics: liver regeneration and hepatocellular carcinoma |
| Q36759538 | Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes |
| Q36547263 | Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma |
| Q27002547 | Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies |
| Q37658691 | Keratin 19: a key role player in the invasion of human hepatocellular carcinomas |
| Q90709960 | Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma |
| Q35212779 | Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients |
| Q38702994 | Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? |
| Q37939073 | Lessons from a decade of integrating cancer copy number alterations with gene expression profiles |
| Q37377572 | Lin28 promotes transformation and is associated with advanced human malignancies |
| Q36917485 | Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. |
| Q38176242 | Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning. |
| Q35903794 | Liver cancer: Approaching a personalized care |
| Q42580571 | Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation |
| Q53219514 | Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. |
| Q34474525 | Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma |
| Q34013536 | Lung adenocarcinoma subtypes based on expression of human airway basal cell genes |
| Q37879671 | MAGED1: molecular insights and clinical implications |
| Q50948001 | MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway. |
| Q46115260 | Major achievements in hepatocellular carcinoma |
| Q34972161 | Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates |
| Q38441297 | Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma. |
| Q61445639 | Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes |
| Q92753090 | Metabolism-associated molecular classification of hepatocellular carcinoma |
| Q36924035 | MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a |
| Q91726315 | MicroRNAs in Animal Models of HCC |
| Q41874690 | Molecular Profiling and Research of Therapeutic Targets |
| Q57064741 | Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy |
| Q37295260 | Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections |
| Q36955912 | Molecular approaches to treatment of hepatocellular carcinoma |
| Q42610253 | Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. |
| Q28383646 | Molecular classification and novel targets in hepatocellular carcinoma: recent advancements |
| Q84403214 | Molecular classification of hepatocellular carcinoma |
| Q88281388 | Molecular classification of hepatocellular carcinoma: The view from metabolic zonation |
| Q43059019 | Molecular classification of hepatocellular carcinoma: potential therapeutic implications |
| Q33680701 | Molecular genetics of hepatocellular neoplasia. |
| Q53290333 | Molecular pathogenesis of hepatocellular carcinoma. |
| Q34954493 | Molecular pathology of hepatic neoplasms: classification and clinical significance |
| Q58020775 | Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial |
| Q52583955 | Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. |
| Q39214067 | Molecular subtype and response to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro |
| Q37003665 | Molecular targeted therapies in hepatocellular carcinoma |
| Q37766798 | Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives |
| Q57143856 | Molecular therapies and precision medicine for hepatocellular carcinoma |
| Q26766689 | Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis? |
| Q27008537 | Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies |
| Q38233004 | Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. |
| Q38098807 | Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections |
| Q41542420 | NOXIN as a cofactor of DNA polymerase-primase complex could promote hepatocellular carcinoma. |
| Q37482829 | NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance |
| Q39012794 | Nanomedicine in management of hepatocellular carcinoma: Challenges and opportunities |
| Q34539069 | Network features suggest new hepatocellular carcinoma treatment strategies |
| Q36090222 | New strategies in hepatocellular carcinoma: genomic prognostic markers. |
| Q36421780 | Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice |
| Q26851211 | Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development |
| Q38933901 | On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. |
| Q28292533 | Oncofetal gene SALL4 in aggressive hepatocellular carcinoma |
| Q43035203 | Oncogenetic tree modeling of human hepatocarcinogenesis |
| Q35698850 | Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice |
| Q26797525 | Overexpression of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 (LGR5) Represents a Typical Wnt/β-Catenin Pathway-Activated Hepatocellular Carcinoma |
| Q39662634 | Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma |
| Q33907588 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. |
| Q26738860 | Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection |
| Q47398654 | Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma |
| Q37132025 | Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling regulates mitochondrial biogenesis and respiration via estrogen-related receptor α (ERRα). |
| Q36157238 | Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/β-catenin Signaling in the Liver |
| Q37183244 | Pivotal role of mTOR signaling in hepatocellular carcinoma |
| Q30372383 | Polymeric Nanostructures for Imaging and Therapy |
| Q48012865 | Potential molecular signatures in epithelial ovarian cancer by genome wide expression profiling |
| Q41547474 | Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy |
| Q41761530 | Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit? |
| Q90469867 | Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation |
| Q33715750 | Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties |
| Q91987072 | Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma |
| Q91178796 | R-spondin 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent Manner |
| Q45916179 | Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. |
| Q34268708 | Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo |
| Q102369375 | Reciprocal REGγ-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma |
| Q35147588 | Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma |
| Q33944599 | Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer |
| Q39356122 | Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts |
| Q33836285 | Retrotransposons: a new and credible source of inherited and somatically acquired hepatocellular carcinoma mutations |
| Q36625697 | Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma |
| Q33683019 | SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. |
| Q36300613 | SRC-2-mediated coactivation of anti-tumorigenic target genes suppresses MYC-induced liver cancer |
| Q35911679 | Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib |
| Q37619600 | Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. |
| Q39409326 | Serum and glucocorticoid kinase 3 at 8q13.1 promotes cell proliferation and survival in hepatocellular carcinoma. |
| Q36438132 | Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. |
| Q37972804 | Signaling pathways in hepatocellular carcinoma. |
| Q33766930 | Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma |
| Q47586118 | Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors. |
| Q97425349 | Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells |
| Q97686325 | Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies |
| Q37857056 | Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. |
| Q41143523 | Suppression of the Wnt signaling pathway may contribute to the inhibition of proliferation of human hepatocellular carcinoma SMMC-7721 cells by esculetin |
| Q91940386 | Synergistic activity of magnolin combined with B-RAF inhibitor SB590885 in hepatocellular carcinoma cells via targeting PI3K-AKT/mTOR and ERK MAPK pathway |
| Q47126606 | TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis. |
| Q37190089 | TGF-β1 and TGF-β2 abundance in liver diseases of mice and men |
| Q36928888 | Targeted therapies for hepatocellular carcinoma. |
| Q98386015 | Targeted therapy for hepatocellular carcinoma |
| Q37449058 | Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab |
| Q26830194 | Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends |
| Q28820734 | The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models |
| Q53244096 | The HOX gene network in hepatocellular carcinoma. |
| Q37363464 | The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals |
| Q100946379 | The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma |
| Q38151262 | The therapeutic potential of bone marrow-derived mesenchymal stromal cells on hepatocellular carcinoma. |
| Q41740984 | The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer |
| Q38472348 | The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers |
| Q33772571 | Transcriptional dissection of pancreatic tumors engrafted in mice. |
| Q42774674 | Transcriptomic analysis of a transgenic zebrafish hepatocellular carcinoma model reveals a prominent role of immune responses in tumour progression and regression |
| Q36106479 | Transcriptomic analysis of the woodchuck model of chronic hepatitis B |
| Q52699075 | Transforming growth factor-β in liver cancer stem cells and regeneration. |
| Q64055612 | Transketolase (TKT) activity and nuclear localization promote hepatocellular carcinoma in a metabolic and a non-metabolic manner |
| Q38008950 | Translational medicine in hepatocellular carcinoma |
| Q37619791 | Treatment with an SLC12A1 antagonist inhibits tumorigenesis in a subset of hepatocellular carcinomas |
| Q26744100 | Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges |
| Q37800793 | Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets |
| Q92661465 | Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma |
| Q42090033 | Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells |
| Q38812372 | Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma |
| Q37632823 | UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma |
| Q36957393 | USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds |
| Q27853116 | Unique genomic profile of fibrolamellar hepatocellular carcinoma |
| Q36997259 | Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma |
| Q46126845 | VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities |
| Q36247123 | Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. |
| Q36048228 | YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression |
| Q54486189 | [Genome-wide molecular screening for the identification of new targets in human hepatocellular carcinoma]. |
| Q47151341 | aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variations. |
| Q64068394 | miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions |
| Q38796985 | microRNA-497 inhibits invasion and metastasis of colorectal cancer cells by targeting vascular endothelial growth factor-A. |
| Q37042920 | p16 Stimulates CDC42-dependent migration of hepatocellular carcinoma cells |
| Q92665666 | β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma |
| Q86011497 | β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study |
Search more.